Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Augmentation of Sertraline in Depression
NCT00485862Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Sertraline + Atomoxetine with Sertraline + Placebo (2 arms). Primary endpoint: Reduction in depressive symptoms at 8 weeks. Started Jun 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00485862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485862.